On Tuesday, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) was -9.30% drop from the session before settling in for the closing price of $8.71. A 52-week range for FDMT has been $2.23 – $12.34.
Healthcare Sector giant saw their annual sales slid by -9.89% over the last five years. When this article was written, the company’s average yearly earnings per share was at -9.35%. With a float of $52.01 million, this company’s outstanding shares have now reached $57.14 million.
The firm has a total of 227 workers. Let’s measure their productivity.
4D Molecular Therapeutics Inc (FDMT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward 4D Molecular Therapeutics Inc stocks. The insider ownership of 4D Molecular Therapeutics Inc is 8.97%, while institutional ownership is 65.83%. The most recent insider transaction that took place on Dec 20 ’25, was worth 3,377. In this transaction VP, Finance and Controller of this company sold 389 shares at a rate of $8.68, taking the stock ownership to the 46,218 shares. Before that another transaction happened on Dec 16 ’25, when Company’s Chief Legal Officer sold 1,635 for $10.90, making the entire transaction worth $17,822. This insider now owns 3,594 shares in total.
4D Molecular Therapeutics Inc (FDMT) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.9 earnings per share (EPS) during the time that was less than consensus figure (set at -0.84) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.93 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.65% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
You can see what 4D Molecular Therapeutics Inc (FDMT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3761.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.94, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -3.48 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Analysing the last 5-days average volume posted by the [4D Molecular Therapeutics Inc, FDMT], we can find that recorded value of 2.38 million was better than the volume posted last year of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 7.13%.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 38.59%, which indicates a significant increase from 2.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.86 in the past 14 days, which was higher than the 0.72 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.60, while its 200-day Moving Average is $6.34. Now, the first resistance to watch is $8.41. This is followed by the second major resistance level at $8.93. The third major resistance level sits at $9.23. If the price goes on to break the first support level at $7.59, it is likely to go to the next support level at $7.29. Now, if the price goes above the second support level, the third support stands at $6.77.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
There are 57,135K outstanding shares of the company, which has a market capitalization of 451.37 million. As of now, sales total 40 K while income totals -160,870 K. Its latest quarter income was 90 K while its last quarter net income were -56,880 K.
